First patient dosed in registrational clinical trial of mesutoclax for the treatment of BTKi-experienced mantle cell lymphoma in China August 26, 2025
European Commission Approves Tablet Formulation of BRUKINSA® for All Approved Indications August 26, 2025
CIT Therapeutics Forms Strategic Partnership with IFLI, Securing Up to $2.5M to Advance Novel Cancer Therapies August 19, 2025
Ph 3 EPCORE® FL-1 Trial Met Dual Primary Endpoints in Patients with R/R Follicular Lymphoma August 12, 2025
FDA Grants Priority Review to Breyanzi (lisocabtagene maraleucel) for R/R Marginal Zone Lymphoma August 11, 2025
Patient death triggers switch to standard FC Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in 1L Consolidation for LBCL August 5, 2025
Complete Response Reported in Heavily Pre-Treated Lymphoma Patient with LP-284 in Ph 1 Trial July 29, 2025
FDA issues CRL for Supplemental BLA for Columvi® (glofitamab-gxbm) + GemOx combo for R/R DLBCL patients not candidates for autoSCT July 23, 2025
Encouraging Response Rates Announced from Ph 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL July 15, 2025
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach July 8, 2025
IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of 1L MCL patients eligible for autologous stem cell transplant July 1, 2025
FDA grants Fast Track Designation for SGR-1505 for the Treatment of R/R Waldenström Macroglobulinemia July 1, 2025
Marker Therapeutics and Cellipont Bioservices to Advance cGMP Manufacturing of MT-601 for Patients with Lymphoma June 24, 2025
Enterome raises $19M to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma June 24, 2025
First Data from MZL Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) Presented June 24, 2025
Positive Ph 2 interim results in R/R indolent NHL after EO2463 OncoMimics immunotherapy treatment presented June 24, 2025
Positive New Clinical Data Demonstrating High Rates of Durable CRs from the Ph 1/2 Trial of LYL314 in Aggressive Large B-cell Lymphoma Announced June 24, 2025
Lunsumio and Polivy Combination Significantly Prolongs Remission for People With R/R Large B-Cell Lymphoma June 24, 2025
FDA Approves Monjuvi (tafasitamab-cxix), Rituximab, and Lenalidomide Combination for Patients with R/R Follicular Lymphoma June 24, 2025
